Lexaria Bioscience Corp. income statement LEXX

Annual Quarterly

In Q3 of fiscal 2026, the quarter ended May 31, 2026, Lexaria Bioscience Corp. reported revenue of $0, down 100.0% from the same quarter a year earlier. It recorded a net loss of $2.0 million. Diluted earnings per share were -$0.08.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM May 31, 2026	Q3 FY2026 May 31, 2026	Q2 FY2026 Feb 28, 2026	Q1 FY2026 Nov 30, 2025	Q4 FY2025 Aug 31, 2025	Q3 FY2025 May 31, 2025	Q2 FY2025 Feb 28, 2025	Q1 FY2025 Nov 30, 2024	Q4 FY2024 Aug 31, 2024
Revenue	0 -68.5%	0 -100.0%	0 -88.5%	0 -100.0%	0 +107.1%	0 +107.1%	0 +20.0%	0	0 +173.3%
Cost of revenue	0 -100.0%	0	0	0 -100.0%	0	0	0	0	0
Gross profit	0 -68.4%	0 -100.0%	0 -88.5%	0 -100.0%	0 +107.1%	0 +107.1%	0 +20.0%	0	0 +173.3%
Research and development	4 -45.4%	1 -64.3%	0 -71.8%	1 -65.6%	2 +94.6%	3 +374.2%	2 +585.9%	2	1 +93.3%
Selling, general and administrative	4 -16.7%	1 -15.2%	1 -19.6%	1 -1.8%	1 -25.7%	1 -3.7%	1 +118.4%	1	1 +104.8%
Operating expenses	8 -34.2%	2 -49.2%	1 -49.7%	2 -45.2%	3 +25.2%	4 +114.8%	3 +259.8%	3	2
Operating income	-8 +32.4%	-2 +46.8%	-1 +47.2%	-2 +41.5%	-3 -22.0%	-4 -115.2%	-3 -311.8%	-3	-2
Interest income	0	0 +340.5%	0	0 +9.1%	0	0	—	0	—
Other income (expense)	-0	0 +102.1%	0 -94.8%	-0	-0	-0	0	—	—
Pretax income	—	-2	—	—	—	—	—	—	—
Income tax	—	0	0	0	—	—	—	—	—
Net income	-8 +32.1%	-2 +47.4%	-1 +46.6%	-2 +41.0%	-3 -23.4%	-4 -112.7%	-3 -317.7%	-3	-2 -76.3%
Diluted EPS	-0.34	-0.08 +61.9%	-0.06 +60.0%	-0.07 +56.2%	-0.14	-0.21	-0.15	-0.16	—
Weighted average shares, diluted	23	25 +35.6%	24 +39.6%	21 +28.2%	20	18	18	17	—
Other measures
Depreciation and amortization	0	0 -36.0%	0 +60.4%	0 +37.5%	0 -26.6%	0 +44.3%	0 -80.5%	0	0 -76.9%
EBITDA	-8	-2 +46.9%	-1 +47.6%	-2 +41.8%	-3 -22.4%	-4 -115.8%	-3 -340.0%	-3	-2
Margins
Gross margin	100.00%	—	100.00%	—	100.00%	100.00%	100.00%	98.52%	100.00%
Operating margin	-3,973.16%	—	-7,259.52%	—	-1,545.17%	-2,155.41%	-1,581.04%	-1,462.95%	-2,622.70%
Profit margin	-3,985.58%	—	-7,249.89%	—	-1,549.33%	-2,177.64%	-1,559.32%	-1,470.02%	-2,600.94%
EBITDA margin	-3,946.39%	—	-7,189.49%	—	-1,538.27%	-2,142.91%	-1,576.02%	-1,458.20%	-2,603.21%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: LEXX (Nasdaq)
Fiscal year ends: August 31
Incorporated in: NV
Headquarters: Kelowna, British Columbia, Canada
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1348362
Former names: Lexaria Corp. (until May 11, 2016); LEXARIA CORP. (until May 11, 2016)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.